Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...

Shares of Amgen (AMGN) added more than 3% in pre-market trading, rebounding from a 7.1% retreat in the previous ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

On Thursday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $321.91 which represents a slight increase of $0.12 or 0.04% from the prior close of $321.79. The stock opened at $322 and ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Buy AMGN near 309.46 target 330.59 stop loss @ 308.57 Details The technical summary data tells us to buy AMGN near 309.46 ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...